-
公开(公告)号：US20170204158A1
公开(公告)日：2017-07-20
申请号：US15463910
申请日：2017-03-20
IPC分类号： C07K14/715 , A61K39/395 , A61K45/06
CPC分类号： C07K14/7155 , A61K38/00 , A61K39/3955 , A61K45/06 , C07K2319/30 , C07K2319/32 , C07K2319/735
摘要： The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.
-
2.发明授权Methods for treating pruritus by administering an antibody that specifically binds human PAR2 有权通过施用特异性结合人PAR2的抗体来治疗瘙痒的方法公开(公告)号：US08425907B2
公开(公告)日：2013-04-23
申请号：US13325098
申请日：2011-12-14
申请人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
发明人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76
摘要： The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.
摘要翻译： 本发明提供了通过阻断人蛋白酶活化的受体-2（PAR2）活性来治疗瘙痒的方法。 本发明的方法可用于治疗与特应性皮炎，银屑病，烧伤瘢痕，肥大性瘢痕形成，瘢痕疙瘩，肾衰竭或肝衰竭相关的瘙痒。 本发明的方法包括施用特异性结合人PAR2的抗体或其抗原结合片段。
-
3.发明申请公开(公告)号：US20110059095A1
公开(公告)日：2011-03-10
申请号：US12877133
申请日：2010-09-08
申请人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
发明人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
IPC分类号： A61K39/395 , C07K16/28 , A61P29/00 , A61P17/04 , A61P11/06 , A61P19/02 , A61P1/00 , A61P1/04 , A61P1/18 , A61P35/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76
摘要： The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.
摘要翻译： 本发明提供了结合蛋白酶激活的受体-2（PAR-2）的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人类PAR-2结合的完全人抗体。 本发明的抗体尤其用于治疗与一种或多种PAR-2生物活性相关的疾病和病症，包括治疗疼痛病症，炎性病症和胃肠病症。
-
4.发明授权公开(公告)号：US08101724B2
公开(公告)日：2012-01-24
申请号：US12877133
申请日：2010-09-08
申请人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
发明人： Lynn MacDonald , Andrew J. Murphy , Nicholas J. Papadopoulos , Marc R. Morra , Robert R. Salzler , Michael L. LaCroix-Fralish
IPC分类号： C12P21/08 , A61K39/00 , A61K39/395 , C07K16/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76
摘要： The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.
摘要翻译： 本发明提供了结合蛋白酶激活受体-2（PAR-2）的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人类PAR-2结合的完全人抗体。 本发明的抗体可用于治疗与一种或多种PAR-2生物活性相关的疾病和病症，包括治疗疼痛病症，炎性病症和胃肠病症。
-
5.发明授权公开(公告)号：US08568721B2
公开(公告)日：2013-10-29
申请号：US13462938
申请日：2012-05-03
申请人： Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人： Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K31/4706 , A61K31/519 , A61K31/655 , A61K38/191 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/248 , C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S514/885 , A61K2300/00
摘要： The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
摘要翻译： 本发明提供使用特异性结合人白细胞介素-6受体（hIL-6R）的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。 本发明的方法可以包括施用第二治疗剂，例如非甾体抗炎药（NSAID），糖皮质激素，疾病缓解性抗风湿药（DMARD）中的一种或多种，或 TNF-α拮抗剂，T细胞阻断剂，抗CD20抗体，IL-1，JAK或IL-17拮抗剂或其任何组合。
-
公开(公告)号：US08338135B2
公开(公告)日：2012-12-25
申请号：US13309594
申请日：2011-12-02
申请人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
发明人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
IPC分类号： C12P21/08
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.
摘要翻译： 提供了通过表面等离振子共振测量的以小于200pM的亲和常数（KD）结合人白细胞介素-4受体α（hIL-4Rα）的分离的人抗体或其抗原结合片段。
-
7.发明授权公开(公告)号：US08192741B2
公开(公告)日：2012-06-05
申请号：US13286261
申请日：2011-11-01
申请人： Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人： Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K31/4706 , A61K31/519 , A61K31/655 , A61K38/191 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/248 , C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S514/885 , A61K2300/00
摘要： The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
摘要翻译： 本发明提供使用特异性结合人白细胞介素-6受体（hIL-6R）的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。 本发明的方法可以包括施用第二治疗剂，例如非甾体抗炎药（NSAID），糖皮质激素，疾病缓解性抗风湿药（DMARD）中的一种或多种，或 TNF-α拮抗剂，T细胞阻断剂，抗CD20抗体，IL-1，JAK或IL-17拮抗剂或其任何组合。
-
公开(公告)号：US20120003697A1
公开(公告)日：2012-01-05
申请号：US13230081
申请日：2011-09-12
申请人： Sean STEVENS , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人： Sean STEVENS , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
摘要翻译： 提供了以约500pM以下的KD结合人IL-6受体（hIL-6R）的人抗体或抗原结合片段，并且以200pM以下的IC 50阻断IL-6活性。 在优选的实施方案中，抗体抗体或抗原结合片段以相对于其结合猴IL-6R至少高2倍的亲和力结合hIL-6R。
-
公开(公告)号：US20100291107A1
公开(公告)日：2010-11-18
申请号：US12821499
申请日：2010-06-23
申请人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
发明人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
IPC分类号： A61K39/395 , A61P17/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
摘要翻译： 本发明提供了治疗一种或多种通过降低白细胞介素-4（IL-4）活性而改善，抑制或改善的疾病或病症的方法。 本发明的方法包括向患者施用特异性结合人IL-4受体的抗体或其抗原结合片段。
-
公开(公告)号：US07605237B2
公开(公告)日：2009-10-20
申请号：US11906517
申请日：2007-10-02
申请人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
发明人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance.
摘要翻译： 通过表面等离振子共振测量，其具有小于200pM的亲和常数（KD）的人白细胞介素-4受体α（hIL-4Ralpha）的分离的人抗体或其抗体片段。
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.03 秒)
